Chronocort European Phase III Study Failure “Surprises” Diurnal, All To Play For In US Studies
Executive Summary
Diurnal has suffered a set-back on its road to approval and commercialization of Chronocort, but analysts still see hope for the product.
You may also be interested in...
Diurnal Adrenal Franchise Takes Shape With Alkindi Launch
With the launch in Germany of Alkindi, Diurnal has kickstarted its plan of offering therapies that treat patients with cortisol deficiency diseases from birth right the way through to old age and the market is potentially a very lucrative one.
Diurnal Nears Market With Novel Adrenal Insufficiency Products
Two potential orphan drugs developed by the UK's newly public endocrinology speciality company, Diurnal Group, are in Phase III clinical trials, and the first of these, Infacort (immediate-release hydrocortisone) for pediatric patients with insufficient levels of the chemically-related essential hormone cortisol, could be approved in its first markets within 18 months, by the end of 2017.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.